Recently Published Hep C Studies, Articles, and Press Releases

Recently Published Hep C Studies, Articles, and Press ReleasesThe following highlights a variety of recently published studies, articles, and press releases  published about hepatitis C and hepatitis C treatments.

Clinical Care Options (June 2016)

Summary: A downloadable audio about the clinical impact of new data reported at the EASL’s International Liver Congress, held in Barcelona, in April. (47 minutes)

Summary: A downloadable slide set.

International Journal of Hepatology (May 2016)

Summary: A review of the current literature about elbasvir/grazoprevir.

Journal of Hepatology (July 2016)

Summary: A list of the benefits of hepatitis C treatment.

Summary: Hep C symptoms and treatment side effects can affect quality of life. This study looked at quality of life during and after treatment with sofosbuvir/velpatasvir. The trial concluded that quality of life was better during and after treatment with sofosbuvir/velpatasvir when compared with a treatment placebo.

Conclusion:  Curing hepatitis C decreases portal pressure, which drives liver-related complications. However, the more damage patients have, the less it heals.

The Lancet Gestroenterology & Hepatology (June 2016)

Summary: Treated 160 patients with hep C genotype 4, with or without liver cirrhosis, for 12 or 24 weeks. Headaches and fatigue were the most common side effects. The study found that the treatment was well tolerated and that longer treatment times didn’t improve cure rate.

Summary: The study looked at the treatment Technivie (ombitasvir/ paritaprevir/ ritonavir) and ribavirin taken for 12 and 16 weeks by patients with hep C genotype 4 and liver cirrhosis. The extended treatment between 12 and 16 weeks didn’t seem to benefit patients.

Recent Pharmaceutical Press Releases